NEW YORK – Medical technology firm Bioloidics said today that it is teaming up with the Agency for Science, Technology and Research's (A*STAR) Genome Institute of Singapore to develop a circulating tumor cell assay that can assess minimal residual disease and predict relapse in women with surgically-treated breast cancer.
Financial and other details were not disclosed. Under the agreement, Singapore-based Biolidics will apply its technology, called ClearCell FX1, to this specific clinical challenge — potentially combining the CTC approach with other circulating biomarkers.
"We want to create a truly next-generation liquid biopsy platform in cancer diagnostics that can detect various forms of cancers at an early stage, thereby leading to lower healthcare costs and better clinical outcomes for patients," Ivan Lew, Biolidics' CEO and executive director, said in a statement.
"With this collaboration with GIS, we can potentially develop an accurate and affordable liquid biopsy test to monitor and predict breast cancer recurrences, thereby enabling medication intervention to prevent a relapse," he added.